| 1 |
35094259 | Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine? | 2022 Feb |
1 |
| 2 |
33418204 | Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial. | 2021 Feb 1 |
1 |
| 3 |
33909316 | Role of serotonin in body weight, insulin secretion and glycaemic control. | 2021 Apr |
1 |
| 4 |
30961494 | Chemistry, Analysis, Pharmacokinetics and Pharmacodynamics Aspects of Lorcaserin, a Selective Serotonin 5-HT2C Receptor Agonist: An Update. | 2020 |
1 |
| 5 |
32079105 | Mechanisms of Action of Cassiae Semen for Weight Management: A Computational Molecular Docking Study of Serotonin Receptor 5-HT2C. | 2020 Feb 16 |
1 |
| 6 |
32642780 | A Validated Stability-Indicating Liquid Chromatographic Method for the Determination of Lorcaserin and Related Impurities in DRUG Substance Supported by Quality by Design. | 2020 Jul 24 |
2 |
| 7 |
30523523 | Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa. | 2019 Jan |
1 |
| 8 |
30689993 | Ligand-directed serotonin 5-HT2C receptor desensitization and sensitization. | 2019 Apr 5 |
3 |
| 9 |
31019729 | Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studies. | 2019 Apr |
1 |
| 10 |
31581577 | Pharmacophore Directed Screening of Agonistic Natural Molecules Showing Affinity to 5HT2C Receptor. | 2019 Oct 1 |
1 |
| 11 |
31774584 | 5-HT2c agonist, lorcaserin, reduces aggressive responding in intermittent explosive disorder: A pilot study. | 2019 Nov |
2 |
| 12 |
29217539 | Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats. | 2018 Mar |
4 |
| 13 |
30233224 | Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release. | 2018 |
1 |
| 14 |
29040827 | Effects of lorcaserin (Belviq®) on nicotine- and food-maintained responding in non-human primates. | 2017 Dec 1 |
1 |
| 15 |
27116910 | Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. | 2016 May |
1 |
| 16 |
24064009 | New and emerging drug molecules against obesity. | 2014 Jan |
1 |
| 17 |
23184281 | Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. | 2013 Apr |
1 |
| 18 |
23529825 | Lorcaserin: a review of its use in chronic weight management. | 2013 Apr |
2 |
| 19 |
23661689 | Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. | 2013 Jul |
1 |
| 20 |
23800750 | New obesity agents: lorcaserin and phentermine/topiramate. | 2013 Jul-Aug |
1 |
| 21 |
24041919 | From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. | 2013 Oct |
1 |
| 22 |
24273398 | Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity. | 2013 Sep |
1 |
| 23 |
24292660 | Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. | 2013 Dec |
1 |
| 24 |
21181547 | Current and future drug targets in weight management. | 2011 Aug |
1 |
| 25 |
22085383 | Serotonergic anti-obesity agents: past experience and future prospects. | 2011 Dec 3 |
1 |
| 26 |
19900026 | Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. | 2009 Nov |
3 |
| 27 |
18252809 | Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. | 2008 May |
5 |